Jardiance

When managing type 2 diabetes, heart failure, or chronic kidney disease, choosing the right medication can feel overwhelming—especially when you’re navigating insurance coverage and medication costs. Two SGLT2 inhibitors, Farxiga (dapagliflozin) and Jardiance (empagliflozin), have emerged as powerful treatment options that go beyond blood sugar control. This comprehensive guide will help you understand the similarities, differences, and practical considerations between these two medications, empowering you to make informed decisions about your healthcare.

Overview of Farxiga and Jardiance

Farxiga and Jardiance belong to a revolutionary class of diabetes medications called SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors). Unlike traditional diabetes drugs that focus solely on insulin or blood sugar, these medications work by blocking a protein in your kidneys that normally reabsorbs glucose back into your bloodstream. Instead, excess glucose is eliminated through urine, providing multiple health benefits beyond diabetes management.

Farxiga (dapagliflozin) was first approved by the FDA in 2014 and has since received additional approvals for heart failure and chronic kidney disease. Manufactured by AstraZeneca, it’s available in 5mg and 10mg tablets and recently became available as a generic medication, making it more affordable for many patients.

Jardiance (empagliflozin), developed by Boehringer Ingelheim and Eli Lilly, received FDA approval in 2014 for the treatment of diabetes and was later approved for additional indications, including heart conditions and kidney disease. Available in 10mg and 25mg strengths, Jardiance remains brand-only, though patient assistance programs can help reduce costs.

The comparison between these medications matters because both have demonstrated remarkable benefits in major clinical trials. They don’t just lower blood sugar—they protect your heart and kidneys while potentially reducing hospitalizations and extending life. For adults over 50, particularly those with multiple health conditions, understanding these differences can be life-changing.

How Farxiga and Jardiance Works

To understand why these medications are so effective, it’s helpful to know how they work in your body. The SGLT2 protein acts like a recycling system in your kidneys, capturing about 90% of the glucose that would otherwise be lost in urine and returning it to your bloodstream. This made sense for our ancestors who faced food scarcity, but in our modern world of abundant calories, this system can work against us.

Both Farxiga and Jardiance block this SGLT2 protein, forcing your kidneys to excrete 60-80 grams of glucose daily through urine. This glucose elimination provides several benefits:

Blood Sugar Improvement: By removing excess glucose, both medications lower A1C levels by 0.5-1.0% when used as monotherapy or added to existing diabetes treatments, according to American Diabetes Association Standards of Care (2023).

Weight Loss: The glucose lost through urine represents approximately 240-320 calories daily, leading to modest but meaningful weight loss of 4-6 pounds over six months for most patients.

Blood Pressure Reduction: The mild diuretic effect and improved blood vessel function typically reduce systolic blood pressure by 2-4 mmHg, providing additional cardiovascular protection.

Heart and Kidney Protection: Beyond these direct effects, SGLT2 inhibitors appear to protect heart muscle cells and kidney cells through mechanisms scientists are still studying, including reduced inflammation and improved cellular energy production.

Key Similarities Between Farxiga and Jardiance

Drug Class and Mechanism

Both medications are SGLT2 inhibitors that block the same protein target in your kidneys. They share the fundamental mechanism of preventing renal glucose reabsorption, leading to glucose excretion through urine. This shared mechanism explains why their benefits and side effect profiles are remarkably similar.

The SGLT2 protein is primarily located in the proximal tubule of your kidneys, where both dapagliflozin and empagliflozin bind reversibly to block glucose reabsorption. This blocking action is dose-dependent, meaning higher doses provide greater glucose elimination, though the relationship isn’t perfectly linear.

Dosing Frequency & Formulations

Both Farxiga and Jardiance offer the convenience of once-daily dosing, typically taken in the morning with or without food. This simple dosing schedule improves medication adherence compared to multiple-daily-dose medications.

Farxiga is available in 5mg and 10mg tablets, with most patients starting at 5mg daily and potentially increasing to 10mg based on tolerance and kidney function. The medication is also available in fixed-dose combinations with metformin (Xigduo XR) and saxagliptin (Qtern).

Jardiance comes in 10mg and 25mg strengths, with 10mg being the typical starting dose for diabetes and heart failure, while 25mg may be used for diabetes management in patients with good kidney function. Fixed-dose combinations include Jardiance with metformin (Synjardy) and with linagliptin (Glyxambi).

Both medications maintain consistent blood levels throughout 24 hours, allowing flexible timing of daily administration. However, taking them at the same time each day optimizes their effectiveness.

Shared Side Effects

The similar mechanism of action between Farxiga and Jardiance results in nearly identical side effect profiles. Understanding these shared risks helps you make informed treatment decisions and know what to monitor.

Genital Yeast Infections: The increased glucose in urine creates an environment that promotes yeast overgrowth. Women experience genital yeast infections in approximately 5-15% of cases, while men may develop balanitis (inflammation of the penis) in 2-4% of cases. Good hygiene and staying well-hydrated can reduce this risk.

Urinary Tract Infections (UTIs): Both medications increase UTI risk by 2-4% compared to placebo. Symptoms include burning during urination, frequent urination, or pelvic pain in women. Adequate fluid intake and proper hygiene help prevent UTIs.

Dehydration and Hypotension: The mild diuretic effect can occasionally lead to dehydration, especially in hot weather, during illness, or with inadequate fluid intake. Signs include dizziness when standing, dry mouth, or decreased urination.

Serious but Rare Risks: Both medications carry black box warnings for rare but serious complications, including diabetic ketoacidosis (even with normal blood sugars), kidney injury, and Fournier’s gangrene (a severe genital infection requiring immediate medical attention).

Critical Differences: Jardiance vs Farxiga

Active Ingredients

While both are SGLT2 inhibitors, the active ingredients differ in their chemical structure and some pharmacological properties.

Dapagliflozin (Farxiga) has a slightly longer half-life of approximately 17 hours and achieves maximum blood concentrations 2-3 hours after dosing. It’s processed primarily by the liver and eliminated through both the kidney and liver pathways.

Empagliflozin (Jardiance) has a shorter half-life of about 12 hours but maintains effective SGLT2 inhibition for 24 hours. It reaches peak levels 1-2 hours after dosing and is eliminated mainly through the kidneys with some liver metabolism.

These pharmacological differences don’t typically translate to clinically meaningful differences in effectiveness or side effects, but they may influence prescribing decisions in patients with severe liver disease.

FDA-Approved Indications

The FDA approvals for these medications have evolved as clinical trial data demonstrated benefits beyond diabetes management.

Farxiga FDA Approvals:

• Type 2 diabetes (adults): Approved 2014
• Heart failure with reduced ejection fraction (HFrEF, adults): Approved 2020
• Chronic kidney disease (adults): Approved 2021
• Heart failure with preserved ejection fraction (HFpEF, adults): Approved 2022
• Type 1 diabetes: Previously approved but withdrawn due to DKA risk

Jardiance FDA Approvals:

• Type 2 diabetes (adults and pediatric patients ≥10 years): Approved 2014
• Heart failure with reduced ejection fraction (HFrEF, adults): Approved 2021
• Chronic kidney disease (adults): Approved 2023

Notably, Jardiance is the only SGLT2 inhibitor approved for pediatric diabetes (children 10 years and older), while Farxiga currently has broader heart failure approvals, including HFpEF.

Generic Availability & Cost Implications

The availability of generic medications can significantly impact your out-of-pocket costs and insurance coverage decisions.

Generic Farxiga (dapagliflozin) became available in early 2024, potentially reducing costs by 80-90% compared to the brand version. Generic availability typically improves insurance coverage and reduces prior authorization requirements.

Brand-Only Jardiance remains under patent protection until approximately 2025-2027. Without generic competition, insurance coverage may require prior authorization or higher copayments. However, manufacturer copay cards can reduce costs for eligible patients.

For uninsured patients, generic dapagliflozin might cost $50-150 per month through discount programs, while brand Jardiance could cost $500-600 monthly without assistance. This price difference makes Farxiga more accessible for many patients on fixed incomes.

How to Take Jardiance vs Farxiga

Type 2 Diabetes

Both medications offer flexible dosing based on your kidney function and treatment response.

Farxiga Diabetes Dosing:

• Starting dose: 5mg once daily in the morning
• Maximum dose: 10mg once daily
• Kidney function requirements: eGFR ≥25 mL/min/1.73m²
• Can be taken with or without food

Jardiance Diabetes Dosing:

• Starting dose: 10mg once daily in the morning
• Maximum dose: 25mg once daily
• Kidney function requirements: eGFR ≥20 mL/min/1.73m²
• Can be taken with or without food

Your doctor may start with lower doses if you have kidney concerns or are taking medications that affect kidney function. Dose increases typically occur after 2-4 weeks if the initial dose is well-tolerated.

Heart Failure (HFrEF and HFpEF)

Heart failure dosing focuses on cardiovascular protection rather than maximum diabetes control.

Farxiga Heart Failure Dosing:

• Standard dose: 10mg once daily
• Used regardless of diabetes status
• Continue unless eGFR falls below 25 mL/min/1.73m²
• Monitor kidney function and volume status

Jardiance Heart Failure Dosing:

• Standard dose: 10mg once daily
• Used in patients with or without diabetes
• Continue unless eGFR falls below 20 mL/min/1.73m²
• Regular monitoring of kidney function is required

Both medications should be continued during heart failure hospitalizations unless acute kidney injury develops. The heart protection benefits occur within weeks of starting treatment.

Chronic Kidney Disease

CKD dosing prioritizes kidney protection while accounting for reduced kidney function.

Farxiga CKD Dosing:

• Standard dose: 10mg once daily
• Used when eGFR 25-75 mL/min/1.73m²
• Continue even as eGFR declines to 25 mL/min/1.73m²
• Monitor for volume depletion

Jardiance CKD Dosing:

• Standard dose: 10mg once daily
• Used when eGFR ≥20 mL/min/1.73m²
• May continue until dialysis initiation
• Regular kidney function monitoring is essential

Both medications slow kidney function decline and may be continued longer than traditional diabetes medications as CKD progresses.

Farxiga vs Jardiance Side Effects

Common Adverse Effects

Understanding common side effects helps you distinguish normal medication effects from serious complications requiring medical attention.

Urogenital Infections (10-15% of patients): Increased glucose in urine promotes bacterial and yeast growth. Women experience more frequent urinary tract infections and vaginal yeast infections. Men may develop balanitis or urinary tract infections. Maintaining good hygiene, staying hydrated, and urinating after sexual activity can reduce infection risk.

Volume Depletion (2-5% of patients): The mild diuretic effect can cause dehydration, particularly in hot weather, during illness with vomiting or diarrhea, or with inadequate fluid intake. Symptoms include dizziness when standing, fatigue, dry mouth, or decreased urination frequency.

Hypoglycemia: When used alone, SGLT2 inhibitors rarely cause low blood sugar. However, when combined with insulin or sulfonylureas, the risk increases. Your doctor may need to reduce doses of these other medications.

Serious Risks

While rare, serious adverse effects require immediate medical attention and careful patient education.

Diabetic Ketoacidosis (DKA): Both medications can trigger DKA even with normal blood glucose levels. Risk factors include severe illness, surgery, prolonged fasting, excessive alcohol intake, or sudden insulin reduction. Symptoms include nausea, vomiting, abdominal pain, difficulty breathing, or fruity breath odor. Stop the medication and seek immediate medical care if DKA is suspected.

Acute Kidney Injury: Dehydration or volume depletion can precipitate kidney injury, particularly in elderly patients or those taking ACE inhibitors or diuretics. Regular kidney function monitoring is essential, especially during illness or medication changes.

Lower Limb Amputations: Clinical trials showed a small increased risk of toe and foot amputations, primarily in patients with existing circulation problems or previous amputations. Good foot care and regular podiatry visits are important for high-risk patients.

Fournier’s Gangrene: This rare but life-threatening genital infection requires emergency surgery. Symptoms include severe genital or perineal pain, swelling, fever, or malaise. Though extremely rare (fewer than 1 in 10,000 patients), immediate medical evaluation is crucial if these symptoms develop.

Special Populations

Elderly Patients: Adults over 65 may experience more frequent side effects, particularly dehydration and impaired kidney function. Starting with lower doses and more frequent monitoring is often recommended.

Pregnancy and Breastfeeding: Neither medication is recommended during pregnancy due to potential kidney effects on the developing fetus. Women planning pregnancy should discuss alternative diabetes treatments with their healthcare provider.

Surgical Procedures: Stop SGLT2 inhibitors 3 days before major surgery or procedures requiring prolonged fasting to reduce DKA risk. Resume after normal eating patterns return and kidney function is stable.

Farxiga vs Jardiance Cost

Retail Prices in the U.S. and Canada

Understanding medication costs helps you budget for long-term treatment and explore savings opportunities.

Average Monthly Costs (in U.S.):

According to online sources, the average price of generic Farxiga at U.S. retail pharmacies typically costs between $330 and $765 for a 30-day supply, depending on the pharmacy chain and dosage.

The average out-of-pocket cost for brand Farxiga at U.S. retail pharmacies ranges from about $580 to $830 for a 30-day supply when purchased without insurance

The average out-of-pocket cost for brand-name Jardiance at U.S. retail pharmacies ranges from about $620 to $875 for a 30-day supply, depending on the pharmacy and location.

Average Monthly Costs (in Canada)

The average price of Farxiga at a Canadian pharmacy through PrescriptionPoint.com is approximately $133 to $256. This means you save between $324 and $697 by purchasing Farxiga from Canada.

Canadian pharmacy pricing through PrescriptionPoint.com offers Jardiance for $54.90 to $328.30, representing potential savings of $291 to $820 compared to purchasing the same medication in the United States.

Generic vs Brand Pricing Impact

The introduction of generic dapagliflozin has created significant cost advantages for Farxiga over Jardiance.

Generic Advantages:

• 80-90% cost reduction compared to the brand
• Improved insurance coverage with fewer restrictions
• Multiple manufacturers are increasing competition and availability
• Pharmacy discount programs offering additional savings

Brand Considerations:

• Consistent manufacturing and appearance
• Some insurance plans may require brand authorization
• Patient assistance programs may provide comparable savings
• Slightly different inactive ingredients rarely affect tolerability

For most patients on fixed incomes, generic dapagliflozin offers the best value proposition, though individual insurance coverage and assistance program eligibility should guide the final decision.

Can You Switch Between Farxiga and Jardiance?

Switching between SGLT2 inhibitors is generally safe and straightforward, though several clinical considerations guide the decision.

Medical Reasons for Switching:

• Cost and insurance coverage changes
• Side effect differences (though rare)
• Specific FDA approvals for your conditions
• Availability issues or pharmacy preferences

Switching Process: Most doctors recommend stopping one SGLT2 inhibitor and starting the other the next day at the equivalent dose. No washout period is typically necessary since both medications have similar mechanisms and kinetics.

Dose Equivalency: While not perfectly equivalent, general conversions include:

• Farxiga 5mg ≈ Jardiance 10mg
• Farxiga 10mg ≈ Jardiance 10-25mg

Your doctor will consider your kidney function, treatment response, and tolerance when determining the appropriate dose of the new medication.

Monitoring After Switching: Continue regular blood sugar, kidney function, and blood pressure monitoring. Most patients experience no difference in effectiveness or side effects when switching, though individual responses may vary.

Farxiga vs Jardiance: Which Is Better for You?

Choosing between Farxiga and Jardiance requires weighing multiple factors specific to your health conditions, financial situation, and treatment preferences.

Choose Farxiga (dapagliflozin) if:

• Cost is a primary concern, and generic availability matters
• You have heart failure with preserved ejection fraction (broader FDA approval)
• You’re comfortable with the DAPA-HF and DAPA-CKD trial data

Choose Jardiance (empagliflozin) if:

• You’re treating pediatric diabetes (the only SGLT2 inhibitor approved for children)
• Your insurance covers brand Jardiance with low copays
• You prefer medications with the largest kidney trial data (EMPA-KIDNEY)

Consider Your Specific Conditions:

• Diabetes only: Either medication is appropriate; cost may be a deciding factor
• Heart failure: Both show similar benefits; Farxiga has HFpEF approval
• Kidney disease: Both provide kidney protection; consider trial data preferences
• Multiple conditions: Either medication addresses all approved indications

Financial Decision Framework:

• Calculate total monthly costs with insurance and assistance programs
• Consider long-term affordability and potential insurance changes
• Factor in monitoring costs and healthcare visits
• Evaluate generic availability and future cost trends

Clinical Decision Factors:

• Your doctor’s experience and comfort with each medication
• Hospital or healthcare system formulary preferences
• Specific trial data that influenced your doctor’s recommendation
• Your response to the previous SGLT2 inhibitor treatment

Frequently Asked Questions

What is better, Jardiance or Farxiga?

Neither medication is definitively “better” than the other. Both are highly effective SGLT2 inhibitors with nearly identical mechanisms of action and clinical benefits. The choice depends on your specific circumstances:

• For cost-conscious patients: Generic Farxiga typically offers better value
• For pediatric diabetes, Jardiance is the only approved option for children
• For heart failure: Both provide similar cardiovascular protection
• For kidney disease: Both offer substantial kidney protection based on large clinical trials

Your healthcare provider will consider your medical conditions, insurance coverage, and individual factors to determine the most appropriate choice.

Can Farxiga cause diarrhea?

Diarrhea is not a common side effect of Farxiga, occurring in fewer than 3% of patients in clinical trials. However, some people may experience gastrointestinal symptoms, including:

• Mild nausea (especially when starting treatment)
• Occasional stomach upset
• Changes in bowel habits

If you experience persistent diarrhea while taking Farxiga, contact your healthcare provider, as it could indicate:

• Dehydration requiring medical attention
• An unrelated illness or infection
• A rare medication reaction requiring evaluation

Most gastrointestinal side effects resolve within the first few weeks of treatment as your body adjusts to the medication.

Why would a doctor prescribe Farxiga?

Doctors prescribe Farxiga for multiple evidence-based reasons beyond diabetes management:

• Cardiovascular Protection
• Kidney Protection
• Diabetes Management
• Multi-condition Treatment
• Safety Profile

What is the downside of Jardiance?

Like all medications, Jardiance has potential disadvantages to consider:

• Cost Factors
• Common Side Effects
• Serious but Rare Risks
• Volume Depletion
• Drug Interactions
• Lifestyle Considerations

Despite these potential downsides, most patients tolerate Jardiance well, and the cardiovascular and kidney benefits often outweigh the risks for appropriate candidates.

Key Takeaways

Similarities: Both Farxiga and Jardiance are highly effective SGLT2 inhibitors offering once-daily convenience, similar side effect profiles, and proven benefits for diabetes, heart failure, and kidney disease. Clinical trial data show comparable cardiovascular and kidney protection between medications.

Key Differences: Generic Farxiga availability provides significant cost advantages, while Jardiance remains brand-only with higher costs but broader pediatric approval. FDA indications vary slightly, with Farxiga approved for both HFrEF and HFpEF, while Jardiance is approved for pediatric diabetes.

Cost Considerations: Generic dapagliflozin costs 80-90% less than brand options, making it more accessible for uninsured or underinsured patients. For additional savings, consider purchasing from licensed Canadian pharmacies through PrescriptionPoint.com, which offers both medications at significantly reduced prices compared to U.S. retail costs.

Clinical Decision: Choose based on your specific conditions, insurance coverage, and financial situation. Both medications provide substantial health benefits, with the “best” choice depending on individual circumstances rather than the superior efficacy of one over the other.

Safety Monitoring: Both medications require regular kidney function monitoring, adequate hydration, and awareness of rare but serious side effects. Stop medication and seek medical care for signs of diabetic ketoacidosis, severe dehydration, or serious infections.

Long-term Perspective: SGLT2 inhibitors represent a paradigm shift in treating diabetes, heart failure, and kidney disease. The cardiovascular and kidney protection benefits often justify their use even in patients without diabetes, making them valuable long-term investments in your health.

For adults over 50 managing multiple chronic conditions on fixed incomes, both Farxiga and Jardiance offer life-extending benefits that extend far beyond blood sugar control. Work closely with your healthcare provider and pharmacist to navigate insurance coverage, assistance programs, and monitoring requirements to ensure you receive optimal treatment within your budget. To explore cost-effective options, you can buy Farxiga online or buy Jardiance online through verified Canadian pharmacy services that may offer substantial savings on your monthly medication costs.

 

References & Evidence

• McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine. 2019;381(21):1995-2008. (DAPA-HF Trial)
• Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. 2020;383(15):1413-1424. (EMPEROR-Reduced Trial)
• Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020;383(15):1436-1446. (DAPA-CKD Trial)
• EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2023;388(2):117-127. (EMPA-KIDNEY Trial)
• American Diabetes Association. Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Supplement_1).
• Solomon SD, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine. 2022;387(12):1089-1098. (DELIVER Trial)
• Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine. 2021;385(16):1451-1461. (EMPEROR-Preserved Trial)
• FDA Drug Approval Letters and Labels for Farxiga (dapagliflozin) and Jardiance (empagliflozin). Available at: www.fda.gov
• Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 2022.
• American Heart Association. Heart Failure Clinical Practice Guidelines. 2022 Update.